Overview
Karuna Therapeutics developed KarXT (xanomeline-trospium), a novel muscarinic receptor-based treatment for schizophrenia that received FDA approval in 2024 under the brand name Cobenfy, representing the first new mechanism of action for schizophrenia in decades. Karuna was acquired by Bristol Myers Squibb in 2024 for approximately $14 billion.
More in Neuropharmaceuticals
Latest industry news
FDA Grants De Novo Approval to Modius Spero, Clearing First Neuromodulation Device for PTSD
2026-09-03 · Policy
Butterfly Network's BCI Chip Licensing Deal Rattles Investors as Shares Drop Nearly 10%
2026-09-02 · Industry
Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream
2026-09-01 · Industry
FDA Grants CorTec Second Breakthrough Device Designation for Its Brain-Computer Interface
2026-08-31 · Policy
Company details
Category
💊 Neuropharmaceuticals
Location
Boston, USA
Funding
Acquired · Bristol Myers Squibb 2024
Website
www.karunatx.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →